Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.

Ann Surg Oncol 2014 Jun 19;21(6):1781-91. Epub 2014 Mar 19.

Department of Medicine, University of Wisconsin School of Medicine and Public Health (UWSMPH), Madison, WI, USA,

Background: Survival benefit from adjuvant chemotherapy is established for stage III colon cancer; however, uncertainty exists for stage II patients. Tumor heterogeneity, specifically microsatellite instability (MSI), which is more common in right-sided cancers, may be the reason for this observation. We examined the relationship between adjuvant chemotherapy and overall 5-year mortality for stage II colon cancer by location (right- vs left-side) as a surrogate for MSI.

Methods: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified Medicare beneficiaries from 1992 to 2005 with AJCC stage II (n = 23,578) and III (n = 17,148) primary adenocarcinoma of the colon who underwent surgery for curative intent. Overall 5-year mortality was examined with Kaplan-Meier survival analysis and Cox proportional hazards regression with propensity score weighting.

Results: It was found that 18 % of stage II patients (n = 2941) with right-sided cancer and 22 % (n = 1693) with left-sided cancer received adjuvant chemotherapy. After adjustment, overall 5-year survival benefit from chemotherapy was observed only for stage III patients (right-sided: hazard ratio [HR], 0.64; 95 % CI, 0.59-0.68; p < .001 and left-sided: HR, 0.61; 95 % CI, 0.56-0.68; p < .001). No survival benefit was observed for stage II patients with either right-sided (HR, 0.97; 95 % CI, 0.87-1.09; p = .64) or left-sided cancer (HR, 0.97; 95 % CI, 0.84-1.12; p = .68).

Conclusions: Among Medicare patients with stage II colon cancer, a substantial number receive adjuvant chemotherapy. Adjuvant chemotherapy did not improve overall 5-year survival for either right- or left-sided colon cancers. Our results reinforce existing guidelines and should be considered in treatment algorithms for older adults with stage II colon cancer.

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1245/s10434-014-3631
Web Search
https://www.vumc.nl/afdelingen-themas/41463/27797/2089686/49
Web Search
http://link.springer.com/10.1245/s10434-014-3631-8
Publisher Site
http://dx.doi.org/10.1245/s10434-014-3631-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016118PMC
June 2014
28 Reads

Publication Analysis

Top Keywords

adjuvant chemotherapy
16
colon cancer
12
5-year mortality
8
stage iii
8
stage patients
8
seer-medicare data
8
survival benefit
8
stage
7
cancer
5
colon underwent
4
analysis cox
4
adenocarcinoma colon
4
primary adenocarcinoma
4
n = 17148 primary
4
underwent surgery
4
surgery curative
4
kaplan-meier survival
4
examined kaplan-meier
4
intent 5-year
4
curative intent
4

References

(Supplied by CrossRef)

NIH Consensus Conference et al.
JAMA. 1990

AB Benson 3rd et al.
J Clin Oncol. 2004

D Schrag et al.
J Clin Oncol. 2002

ES O’Connor et al.
J Clin Oncol. 2011

G Lanza Jr et al.
Mod Pathol. 1994

JA Bufill et al.
Ann Intern Med. 1990

B Iacopetta et al.
Int J Cancer. 2002

OK Glebov et al.
Cancer Epidemiol Biomarkers Prev. 2003

K Birkenkamp-Demtroder et al.
Gut. 2005

P Gervaz et al.
J Surg Oncol. 2004

CM Ribic et al.
N Engl J Med. 2003

Similar Publications